MDT 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-09-03

• Fiscal year 2027 is a 53-week fiscal year, with the extra week occurring in the first fiscal month of the first quarter and included in the three months ended July 31, 2026 results.

• The following is a summary of net sales, diluted earnings per share, and operating cash flow for the three months ended July 31, 2026:

• The tables below present our GAAP to non-GAAP reconciliations for the three months ended July 31, 2026 and July 25, 2025:

• (1)The charges primarily relate to employee termination benefits, facility related and contract termination costs, and asset write offs.

• (2)The charges primarily include business combination costs, changes in fair value of contingent consideration, and exit of business-related charges. Exit of business-related charges primarily relate to the impending separation of the Diabetes Business and costs associated with the Company's June 20…

相对上期删除的文字 · 来源:10-Q · 2026-02-24

• The following is a summary of net sales and diluted earnings per share for the three months ended January 23, 2026 and January 24, 2025 and operating cash flow for the nine months ended January 23, 2026 and January 24, 2025:

• The tables below present our GAAP to Non-GAAP reconciliations for the three months ended January 23, 2026 and January 24, 2025:

• (1)The Company recognized $30 million of accelerated amortization on certain intangible assets within the Cardiovascular Portfolio.

• (2)The charges primarily relate to employee termination benefits, facility related and contract termination costs, and asset write offs.

• (3)The charges primarily include business combination costs, changes in fair value of contingent consideration, exit of business-related charges, and gains related to certain business or asset sales. Exit of business-related charges primarily relate to the impending separation of the Diabetes busine…

相对上期新增的文字 · 来源:10-Q · 2026-09-03

• During the quarter ended July 31, 2026, the following officer adopted a “Rule 10b5-1 trading arrangements” intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act as follows.

• On July 16, 2026, Geoff Martha, Chairman and Chief Executive Officer, adopted a Rule 10b5-1 trading plan. The trading plan provides for the sale of up to 50,000 shares of the Company’s common stock starting as early as October 15, 2026, prior to the plan's termination date of November 30, 2026.

• Medtronic has engaged in certain activities that it is required to disclose pursuant to Section 13(r)(1)(D)(ii) of the Securities Exchange Act of 1934, as amended. In particular, during the first quarter of fiscal year 2027, Medtronic engaged in certain regulatory activities involving Russia’s Feder…

• During the first quarter of fiscal year 2027 ending July 31, 2026, in the normal course of business and consistent with the Office of Foreign Assets Control ("OFAC") authorizations as in effect at the time, Medtronic Russia filed three notifications with the FSB, as required under local Russian law …

相对上期删除的文字 · 来源:10-Q · 2026-02-24

• During the quarter ended January 23, 2026, none of our directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" as defined in Item 408 of Regulation S-K.